Testing deucravacitinib for active Takayasu's arteritis
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This study tests a new pill called deucravacitinib for people with active Takayasu's arteritis (a rare blood vessel disease). It aims to see if the drug can help control inflammation when other treatments have not worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older and have been diagnosed with Takayasu's arteritis.
- Your disease is still active or has come back despite treatment with steroids and other immune-suppressing drugs (but not TNF blockers).
- A recent PET scan shows active inflammation in your arteries.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use highly effective birth control.
- You have not tried a TNF blocker (like adalimumab) and stopped because it didn't work or you couldn't tolerate it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new medications, vunakizumab and ivarmacitinib, for people with active Takayasu's arteritis (TAK) that is not fully controlled by standard treatments. The goal is to see if these drugs are safe and effective for reducing disease activity.
This study tests whether ultrasound can track inflammation in blood vessels for people with Takayasu arteritis (a rare condition causing vessel inflammation). You'll have regular ultrasounds to see if this method helps doctors spot disease activity early.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
This trial tests a medication called secukinumab for people with active, severe Takayasu arteritis, a disease that causes inflammation in large blood vessels. The goal is to see if secukinumab can help control the disease better than standard treatments alone.
This trial tests adding a new oral medication (deucravacitinib) to your current anti-TNF therapy to see if it helps better control psoriatic arthritis or psoriasis that hasn't improved enough. It may be an option if you still have active symptoms despite being on a stable anti-TNF treatment for at least 6 months.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
Hear when a new Takayasu Arteritis (TAK) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.